Cell & Gene Therapies
— When precision is paramount
When transporting cell & gene therapies, precision is non-negotiable and there are no second chances.
Exposure to incorrect temperatures, even for short periods, can compromise the potency, safety, and viability of these treatments, leading to significant financial losses and, more importantly, potential harm to patients. From -150°C to -70°C, we ensure consistent temperature control, mitigating the risks associated with temperature excursions and addressing the specialized needs of cell & gene therapy (CGT) transportation with unparalleled precision.
Key Benefits
We ensure that life-changing treatments reach patients in optimal condition, safeguarding the future of cell and gene therapies and transforming patient lives.
Real-time monitoring
Safeguard the efficacy of your products with real-time Live Monitoring, providing instant visibility into shipment conditions throughout its journey. You can proactively intervene to prevent temperature excursions if the unexpected happens, minimizing product loss and ensuring product efficacy upon arrival.
Precise control
Drawing on 40 years of expertise, our tailored solutions for temperature-sensitive pharmaceuticals enable precise temperature control, from -150°C to +37°C. Rigorously tested against extreme conditions, we ensure product protection throughout its journey, preserving efficacy and stability.
Unbeatable durations
Our CGT solutions offer superior duration of up to 3 weeks. This ensures extended product stability, reducing the risk of product spoilage and ensuring the efficacy of your temperature-sensitive cell & gene therapies upon arrival.
Case Studies
See how leading pharmaceutical companies are overcoming the complex challenges of global transportation with our innovative solutions.
OrthoCell Ltd
Adopting CryoSure® for Shipping Advanced Cell Therapies
Learn how we helped OrthoCell Ltd find the right packaging solution for their shipment – overcoming challenges without compromising on their environmental impact.
Industry Insights
-
Understanding the Complexities of Shipping Rare Disease and Orphan Drugs
Rare and orphan diseases affect a relatively small number of individuals within the global population (less than 200,000 people in the US or less than 5 in 10,000 people in Europe). Due to the high costs associated with research and development and a limited patient pool, companies developing such products often incur a financial loss, and so the pharmaceutical industry has been forced to neglect many rare diseases.
Learn more
-
How the cold chain can provide true global and local access to vital medicines
In this whitepaper, we identify the 4 key areas for improvement to take the cold chain to the next level. For each of these areas, we will discuss the latest advances, technology and best practices in cold chain and how they address the challenges of transporting temperature-sensitive pharmaceuticals globally.
Read the whitepaper
Get in touch
We are here to support you 24/7 with our global customer service. For non-urgent inquiries, please email us at support@ebasd.com or for urgent issues, call our Operations Center.
